These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 30067611)

  • 1. A closer look at blinatumomab.
    Mattison RJ
    Clin Adv Hematol Oncol; 2018 Jun; 16(6):412-414. PubMed ID: 30067611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
    Jen EY; Xu Q; Schetter A; Przepiorka D; Shen YL; Roscoe D; Sridhara R; Deisseroth A; Philip R; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jan; 25(2):473-477. PubMed ID: 30254079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
    Wolach O; Stone RM
    Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA; Rexwinkle A; Autry J; Bryan JC
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinatumomab: first global approval.
    Sanford M
    Drugs; 2015 Feb; 75(3):321-7. PubMed ID: 25637301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
    Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
    Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
    Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Rambaldi A; Ritchie EK; Papayannidis C; Tuglus CA; Morris JD; Stein A
    Eur J Cancer; 2021 Mar; 146():107-114. PubMed ID: 33588145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia.
    Elitzur S; Arad-Cohen N; Barzilai-Birenboim S; Ben-Harush M; Bielorai B; Elhasid R; Feuerstein T; Gilad G; Gural A; Kharit M; Litichever N; Nirel R; Weinreb S; Wolach O; Toren A; Izraeli S; Jacoby E
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27898. PubMed ID: 31264788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
    Litzow MR; Sun Z; Mattison RJ; Paietta EM; Roberts KG; Zhang Y; Racevskis J; Lazarus HM; Rowe JM; Arber DA; Wieduwilt MJ; Liedtke M; Bergeron J; Wood BL; Zhao Y; Wu G; Chang TC; Zhang W; Pratz KW; Dinner SN; Frey N; Gore SD; Bhatnagar B; Atallah EL; Uy GL; Jeyakumar D; Lin TL; Willman CL; DeAngelo DJ; Patel SB; Elliott MA; Advani AS; Tzachanis D; Vachhani P; Bhave RR; Sharon E; Little RF; Erba HP; Stone RM; Luger SM; Mullighan CG; Tallman MS
    N Engl J Med; 2024 Jul; 391(4):320-333. PubMed ID: 39047240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gore L; Locatelli F; Zugmaier G; Handgretinger R; O'Brien MM; Bader P; Bhojwani D; Schlegel PG; Tuglus CA; von Stackelberg A
    Blood Cancer J; 2018 Aug; 8(9):80. PubMed ID: 30190453
    [No Abstract]   [Full Text] [Related]  

  • 20. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
    Halford Z; Coalter C; Gresham V; Brown T
    Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.